Search Results - "Ravandi, F"

New drugs in acute myeloid leukemia by Kadia, T.M., Ravandi, F., Cortes, J., Kantarjian, H.

“…The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications…”
Get full text

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center by Walter, R B, Othus, M, Burnett, A K, Löwenberg, B, Kantarjian, H M, Ossenkoppele, G J, Hills, R K, Ravandi, F, Pabst, T, Evans, A, Pierce, S R, Vekemans, M-C, Appelbaum, F R, Estey, E H

“…Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We used area under receiver-operating characteristic curves (AUCs) to…”
Get full text

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression by DiNardo, C D, Jabbour, E, Ravandi, F, Takahashi, K, Daver, N, Routbort, M, Patel, K P, Brandt, M, Pierce, S, Kantarjian, H, Garcia-Manero, G

Get full text

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson by Othus, M, Kantarjian, H, Petersdorf, S, Ravandi, F, Godwin, J, Cortes, J, Pierce, S, Erba, H, Faderl, S, Appelbaum, F R, Estey, E

“…Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here…”
Get full text

Role of cytokines in the treatment of acute leukemias: a review by RAVANDI, F

“…Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the…”
Get full text

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse by Boddu, P, Jorgensen, J, Kantarjian, H, Borthakur, G, Kadia, T, Daver, N, Alvarado, Y, Pemmaraju, N, Bose, P, Naqvi, K, Yilmaz, M, Pierce, S, Brandt, M, DiNardo, C D, Jabbour, E J, Konopleva, M, Garcia-Manero, G, Cortes, J, Ravandi, F

Get full text

A prognostic score for patients with lower risk myelodysplastic syndrome by Garcia-Manero, G, Shan, J, Faderl, S, Cortes, J, Ravandi, F, Borthakur, G, Wierda, W G, Pierce, S, Estey, E, Liu, J, Huang, X, Kantarjian, H

“…Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may…”
Get full text

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome by Daver, N, Kantarjian, H, Ravandi, F, Estey, E, Wang, X, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Verstovsek, S, Kadia, T, Dinardo, C, Pierce, S, Huang, X, Pemmaraju, N, Diaz-Pines-Mateo, M, Cortes, J, Borthakur, G

“…Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110…”
Get full text

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) by Jain, P., Aoki, E., Keating, M., Wierda, W.G., O’Brien, S., Gonzalez, G.N., Ferrajoli, A., Jain, N., Thompson, P.A., Jabbour, E., Kanagal-Shamanna, R., Pierce, S., Alousi, A., Hosing, C., Khouri, I., Estrov, Z., Cortes, J., Kantarjian, H., Ravandi, F., Kadia, T.M.

“…T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. We reviewed the…”
Get full text

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration by Hoellenriegel, J, Coffey, G P, Sinha, U, Pandey, A, Sivina, M, Ferrajoli, A, Ravandi, F, Wierda, W G, O'Brien, S, Keating, M J, Burger, J A

“…Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation…”
Get full text

Influence of IDH on FLT3-ITD status in newly diagnosed AML by Boddu, P, Takahashi, K, Pemmaraju, N, Daver, N, Benton, C B, Pierce, S, Konopleva, M, Ravandi, F, Cortes, J, Kantarjian, H, DiNardo, C D

Get full text

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation by Chen, Y, Kantarjian, H, Pierce, S, Faderl, S, O'Brien, S, Qiao, W, Abruzzo, L, de Lima, M, Kebriaei, P, Jabbour, E, Daver, N, Kadia, T, Estrov, Z, Garcia-Manero, G, Cortes, J, Ravandi, F

“…The clinical features and outcomes of 148 patients with acute myeloid leukemia (AML) and 11q23 chromosomal abnormalities were compared with those of 2640…”
Get full text

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia by Ravandi, F, Arana Yi, C, Cortes, J E, Levis, M, Faderl, S, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Estrov, Z, Borthakur, G, Thomas, D, Pierce, S, Brandt, M, Pratz, K, Luthra, R, Andreeff, M, Kantarjian, H

Get full text

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome by Kelly, A D, Kroeger, H, Yamazaki, J, Taby, R, Neumann, F, Yu, S, Lee, J T, Patel, B, Li, Y, He, R, Liang, S, Lu, Y, Cesaroni, M, Pierce, S A, Kornblau, S M, Bueso-Ramos, C E, Ravandi, F, Kantarjian, H M, Jelinek, J, Issa, J-PJ

“…Genetic changes are infrequent in acute myeloid leukemia (AML) compared with other malignancies and often involve epigenetic regulators, suggesting that an…”
Get full text

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience by Jain, P, Kantarjian, H, Ravandi, F, Thomas, D, O'Brien, S, Kadia, T, Burger, J, Borthakur, G, Daver, N, Jabbour, E, Konopleva, M, Cortes, J, Pemmaraju, N, Kelly, M A, Cardenas-Turanzas, M, Garris, R, Faderl, S

Get full text

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials by Montalban-Bravo, G, Huang, X, Jabbour, E, Borthakur, G, DiNardo, C D, Pemmaraju, N, Cortes, J, Verstovsek, S, Kadia, T, Daver, N, Wierda, W, Alvarado, Y, Konopleva, M, Ravandi, F, Estrov, Z, Jain, N, Alfonso, A, Brandt, M, Sneed, T, Chen, H-C, Yang, H, Bueso-Ramos, C, Pierce, S, Estey, E, Bohannan, Z, Kantarjian, H M, Garcia-Manero, G

“…Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a…”
Get full text

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML by Takahashi, K, Jabbour, E, Wang, X, Luthra, R, Bueso-Ramos, C, Patel, K, Pierce, S, Yang, H, Wei, Y, Daver, N, Faderl, S, Ravandi, F, Estrov, Z, Cortes, J, Kantarjian, H, Garcia-Manero, G

Get full text

The JAK-STAT pathway: a therapeutic target in hematological malignancies by Ferrajoli, A, Faderl, S, Ravandi, F, Estrov, Z

“…The development and function of hematopoietic cells depends on complex signaling pathways that are mediated by numerous cytokines and their receptors. The…”
Get more information

P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML by Bidikian, A., Kantarjian, H., Jabbour, E., Short, N., Ravandi, F., Issa, G., Sasaki, K.

Get full text

Therapy-related acute promyelocytic leukemia by Ravandi, Farhad

Get full text